Chemotherapy ‘Has Limited Role’ After ICI Failure in Metastatic Melanoma
The objective response rate was 12.5%, and the median progression-free survival was 2.6 months.
The objective response rate was 12.5%, and the median progression-free survival was 2.6 months.
Researchers have summarized what is known about COVID-19 in the context of lung cancer and highlighted areas where more research is needed.
No significant difference observed in 30-day mortality for fully vaccinated versus unvaccinated cancer patients with COVID-19
Other independent predictors of BCRL include receipt of neoadjuvant chemotherapy, older age, increasing amount of time since surgery
Black and Hispanic patients remain underrepresented in cancer trials, despite increased participation from 2015 to 2019.
Unemployment is adversely associated with recommended cancer screening, with the association explained by lack of health insurance.
Patient economic burden associated with cancer care was projected to be $21.1 billion in 2019.
The proportion of all incident cancer cases attributable to physical inactivity is 3.0% overall and varies between states from 2.3 to 3.7%.
A retrospective study of Medicare data showed a potential factor in nonadherence to oral cancer treatment regimens.
The study showed differences by cancer type and race/ethnicity.